Mercados españoles cerrados

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
338,10+0,10 (+0,03%)
Al cierre: 4:00PM EDT
338,10 0,00 (0,00 %)
Después del cierre: 04:10PM EDT
Inicia sesión para publicar un mensaje.
  • s
    sat
    $SAVA conversation
    thank you $biib for the dip
  • O
    O-Behave
    $BIIB conversation
    $LLY news is GREAT news for $BIIB not bad news. The smoke will clear and we will be heading right back to the $400s

    Hedgefunds are loading here. I guarantee it.

    $BIIB: Cowen Upgrades To Outperform PT $450

    Atlantic Equities Upgrades to Neutral - PT $415

    Citigroup Upgrades to Neutral PT $440

    Oppenheimer Raises Target Price To $450 From $325

    Morgan Stanley Raises Target Price To $455 From $343

    Jeffries PT $500

    SEE U AT $600+💸✈📚📈📽
  • O
    O-Behave
    $BIIB conversation
    $BIIB out of 33 analysts CURRENT AVERAGE PRICE TARGET still $420! These bears trying to post fear are AMATEURS. Currently trading at the price target of most analysts BEFORE FDA approval. Friday will be green as cabbage. Someone bought $52 MILLION worth of shares on Wednesday at $374! They're gonna run this soon. Adding 750 shares tomorrow.
  • O
    O-Behave
    $BIIB conversation
    $BIIB Ye just gave a $500 price target on @cnbc minutes ago!💸
  • M
    MrT
    $ACIU conversation
    Just following Dievini (billionaire Hopp) $BIIB FDA tearing it down…
    $SAVA run the hype…
    $ACIU insanely undervalued sleeping giant…@ market cap of 0.5, considering the pipeline with 125 people and impressive IP https://www.acimmune.com/en/pipeline-overview/
  • W
    WealthMastersClub1
    $BIVI conversation
    BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix
    BioVie, Inc.
    Fri, June 11, 2021, 5:00 AM·2 min read

    BIVI
    +16.61%
    Company Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021

    SANTA MONICA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company") today announced the closing of its previously announced acquisition of the biopharmaceutical assets of NeurMedix, Inc., a privately held clinical-stage pharmaceutical company. The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered first-in-class small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance play fundamental roles in the development of Alzheimer’s and Parkinson’s Disease, and NE3107 could represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from Alzheimer’s and 1 million from Parkinson’s. The FDA recently authorized a pivotal US Phase 3 clinical trial for NE3107.
    $AVXL $SAVA $ANVS $BIIB
  • W
    WealthMastersClub1
    $BIVI conversation
    BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®on the Bloomberg Network in the U.S. on this coming Saturday, June 19th, at 7 p.m. local time $ANVS $SAVA $AVXL $BIIB

    To view the interview segment, please visit: https://youtu.be/B9u4xqdT6lc
  • W
    WealthMastersClub1
    $BIVI conversation
    BIVI = Higher ROI
    Company Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021
    $BIIB $ANVS $SAVA $AVXL
  • O
    O-Behave
    $BIIB conversation
    $BIIB Guy Adami recommended it A BUY yesterday. EXTREMELY BULLISH TODAY.
  • T
    Tom
    How important is FDA approval?

    $BIIB jumped 60% at one point today, from $268 to about $430 (estimates, numbers not in front of me) on FDA approval for a new Alzheimer’s drug.

    FDA approval means EVERYTHING! When (🤞🏼🤞🏼) this 180-day receives FDA approval in the Fall we can expect the same reaction.
  • O
    O-Behave
    $BIIB conversation
    $BIIB adding
  • R
    RV
    $NTLA conversation
    They are right- Adami is the better of these guys on CNBC but they do not know much about this science.

    Cathie's Ark
    @cathiesark
    ·
    Jun 28
    Just saw
    @GuyAdami
    on
    @CNBC
    comparing the $NTLA pop to $BIIB's a few weeks ago. Did we already forget that the drug $BIIB popped on barely works?

    Apples and oranges
  • O
    O-Behave
    $BIIB conversation
    We should thank them for giving us $BIIB at a discount.

    Remember 8,000,000 AZH cases in the US need Adulham.

    IF 100,000 take it at $56k it is $5.6B in revenue annually.
  • O
    O-Behave
    $BIIB conversation
    BIIB who gave away their shares??! LMFAOOOOO! $LLY just got a fast track designation this has NOTHING on $BIIB. I'm loading these gifts 🎁
  • O
    O-Behave
    $BIIB conversation
    $BIIB this low volume day is BEAUTIFUL! It signifies that all panic sellers are out. Let's build it organically back above $400. $LLY bad news will circulate soon. Add the BEAUTIFUL news regarding $BIIB eye DRUG and we can look forward to those 450+'s
  • G
    G money cricket
    $BIIB conversation
    congrats BIIB hodlers! If you are looking for other stocks that will rise with $BIIB today, look no further than $ARFXF... they've been pre-Phase I for a while, pending aducanumab approval. Boston sports magnate billionaires from BIIB's neighborhood recently put $7M into $ARFXF. Their PMN310 is basically the next-gen aducanumab with better binding affinity and selectivity, so it can be dosed higher without causing ARIA-E effects that limit dosing of aducanumab. promis neurosciences is the company name. and the market cap is about 1000X smaller than BIIB, so do the math on that...
  • t
    thirdmeinvestor
    $VRTX conversation
    June is a very important month for $VRTX, $BIIB, and all biotechs. JPM's Kasimov's thoughts are here:
    https://finance.yahoo.com/news/fate-biogen-stock-rides-fda-124236090.html
  • O
    O-Behave
    $BIIB conversation
    $BIIB I'm ADDING heavy at these prices today. Unbelievable
  • v
    valuegeek77
    $ANVS conversation
    No matter how you look at it, less than 300 million market cap is too damn low for an AD drug company that has a viable drug (even if it does not work completely)

    AD is difficult to treat and $AVNS, $SAVA and $AVXL has shown they have a drug that at least works partially (just like $BIIB drug)
  • M
    MikeGamechanger
    Today the FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway -- this approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003 $BIIB #Alzheimers